Neopharma - A world class pharmaceutical manufacturing facility in United Arab Emirates

Milestones

»	2011
	Neopharma receives UAE approval for Gliclazide sustained release tablets. Neopharma makes its foray into CIS Markets with product launches in Tajikistan. Neopharma introduces generic version of anti-diarrheal drug Loperamide in UAE. Neopharma begins marketing of its first injectable product “Advacef”. Neopharma launches generic version of Ivy Leaf extract Syrup. Neopharma receives approval for the launch of generic version of Gliclazide Modified Release Tablets. Neopharma receives approval for the launch of Urinary Alkalinizer, Fluconazole tablets and low osmolarity formula of Oral Rehydration Salts Neopharma further expands operations in the African Market by starting the registration process in Ethiopia and Tanzania. Registration of first set of products completed in Turkmenistan. The UAE Genetic Diseases Association and Neopharma have joined hands for introducing Manal. The launch of Manal will form an integral part of the UAE GDA vision to prevent neural tube defects in the United Arab Emirates by Health Education, Public Awareness and Folic Acid Supplementation targeted for specific population.

»	2010
	Neopharma has received the Certificate of EHS approval from the Abu Dhabi Emirate, Environment, Health and Safety Management System.

»	2009
	Products are introduced into one of the biggest markets in the region – Saudi Arabia Neopharma starts Kuwait operations Neopharma moves into horizontal integration mode. Ground breaking ceremony heralds the start of new manufacturing facilities.

»	2008
	Neopharma starts operations in the Sultanate of Oman. Neopharma becomes the first pharmaceutical company in the region to obtain the integrated management system encompassing ISO 9001, ISO 14001 & OHSAS 18001. Contract manufacturing for Lagap, Switzerland Neopharma enters the Qatar pharmaceutical market The first exports to East Africa commences with dispatch to Kenya Neopharma enters the Afghanistan markets

»	2007
	Neopharma and Biocon sign a joint venture, heralding the region’s first biotechnology company – Neobiocon.

»	2006
	Neopharma wins the prestigious Mohammed Bin Rashid Al Maktoum Award in the manufacturing category. Company enters into a joint venture program with the University of Arkansas in the area nanotechnology for deliverables such as nano bio-sensors. Neopharma pioneers the introduction of the region’s first sustained release version of popular antidiabetic product giving patients the convenience of dosage. Neopharma makes first exports to Bahrain

»	2005
	Neopharma receives the GCC DR certificate paving way for the registration of the company across the GCC countries. The manufacturing facilities of Neopharma receive the current EU GMP certificate from Belgium. Neopharma begins exports to Yemen, Libya and Iraq.

»	2004
	Neopharma begins domestic operations as the first set of products roll out from the General Products plant and the Betalactam plant. Exports to Switzerland mark the company’s global foray. In-house team develops and runs an integrated ERP module.

»	2003
	Neopharma – Abu Dhabi’s premier manufacturing facility is inaugurated. Plant equipment undergoes validation studies and gets set for pharmaceutical manufacturing. Neopharma receives the ISO 9001: 2000 for quality management systems.

2011

Neopharma receives UAE approval for Gliclazide sustained release tablets.
Neopharma makes its foray into CIS Markets with product launches in Tajikistan.
Neopharma introduces generic version of anti-diarrheal drug Loperamide in UAE.
Neopharma begins marketing of its first injectable product “Advacef”.
Neopharma launches generic version of Ivy Leaf extract Syrup.
Neopharma receives approval for the launch of generic version of Gliclazide Modified Release Tablets.
Neopharma receives approval for the launch of Urinary Alkalinizer, Fluconazole tablets and low osmolarity formula of Oral Rehydration Salts
Neopharma further expands operations in the African Market by starting the registration process in Ethiopia and Tanzania.
Registration of first set of products completed in Turkmenistan.
The UAE Genetic Diseases Association and Neopharma have joined hands for introducing Manal. The launch of Manal will form an integral part of the UAE GDA vision to prevent neural tube defects in the United Arab Emirates by Health Education, Public Awareness and Folic Acid Supplementation targeted for specific population.

2010

Neopharma has received the Certificate of EHS approval from the Abu Dhabi Emirate, Environment, Health and Safety Management System.

2009

Products are introduced into one of the biggest markets in the region – Saudi Arabia
Neopharma starts Kuwait operations
Neopharma moves into horizontal integration mode. Ground breaking ceremony heralds the start of new manufacturing facilities.

2008

Neopharma starts operations in the Sultanate of Oman.
Neopharma becomes the first pharmaceutical company in the region to obtain the integrated management system encompassing ISO 9001, ISO 14001 & OHSAS 18001.
Contract manufacturing for Lagap, Switzerland
Neopharma enters the Qatar pharmaceutical market
The first exports to East Africa commences with dispatch to Kenya
Neopharma enters the Afghanistan markets

2007

Neopharma and Biocon sign a joint venture, heralding the region’s first biotechnology company – Neobiocon.

More updates...